Navigation Links
Novus Biologicals Hires David Eansor to Lead New Corporate-Development Effort
Date:1/24/2013

LITTLETON, Colo., Jan. 24, 2013 /PRNewswire/ -- Novus Biologicals LLC, a leading provider of antibodies and reagents to the life science research community, has hired David Eansor to lead a new corporate-development effort.

Eansor, a 13-year veteran in the life science market who was most recently the president of Thermo Fisher Scientific's bioscience division, joined Novus in January as senior vice-president of corporate development. In this new role, Eansor is tasked with accelerating Novus' already impressive growth through a combination of organic investments, licensing and acquisitions of complementary products and capabilities.

"I'm thrilled to join Novus, and for the opportunity to create new growth platforms for this innovative company," Eansor said. "I have watched Novus grow from a niche player to a leader in its space, and I've always been impressed with its commitment to scientific research and outstanding customer service."

"We are so pleased to have an executive of David's caliber join our team, and look forward to many stellar contributions as he expands this critical corporate-development function for us," added Karen Padgett , Novus' founder and chief executive.

Before becoming president of the bioscience division of Thermo Fisher , a publicly traded company, Eansor served as president of the life science research division, acquiring three businesses during his tenure.

Prior to that, he was president of Cambrex Bioproducts, another life science research business focused on cell biology. Eansor also spent 19 years with R.P Scherer Corp., a contract pharmaceutical drug-delivery manufacturer which was acquired by Cardinal Health. He holds a degree in chemistry from the University of Western Ontario as well as a bachelor of commerce and an MBA from the University of Windsor, also in Ontario, Canada.

About Novus

Novus Biologicals is a leading digital marketing-driven, life science company that supplies antibodies and reagents to the $6 billion global proteomics market.  Novus is known for its breadth of quality antibodies and reagents that are well recognized by its global customer base.  Based in Littleton, CO, the company was founded in 1996 to license, produce and market antibodies to support niche and emerging areas of research.  Now Novus is a global enterprise with a catalog of 180,000 products sold in 60 countries, mainly through its Web site. Novus is backed by Mainsail Partners, a San Francisco growth-equity firm, and has additional offices in Ontario, Canada and Cambridge, UK.

CONTACT

Karen Padgett , President and CEO

Novus Biologicals, LLC

Karen@novusbio.com

303-730-1950

www.novusbio.com


'/>"/>
SOURCE Novus Biologicals LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
2. PhoenixSongs Biologicals, Inc. Announces Enhanced Neural Lineage-specific Cell Culture Media Products Release
3. PathoGenetix Hires Food Safety Testing Expert John W. Czajka as Vice President of Business Development
4. Ganeden Biotech Hires New Marketing Manager
5. Provia Labs Hires Vice President of International Business Development to Expand Global Distribution for its Stem Cell Banking Service and Biobanking Products
6. Ernst & Young LLP Bolsters Fraud Investigation & Dispute Services with New Hires and Promotions
7. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
8. Textile Company PurThread Technologies Opens Headquarters in Durham, North Carolina and Hires New Senior Staff
9. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
10. Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer
11. David Smith Named Vice President of Operations for HealthTell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 08, 2016 , ... ... services, announced today the launch of its revamped and improved website. In an ... service solutions, the redesigned website will better communicate how the company designs and ...
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove announced today ... National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to work ... throughout the drug regulatory review process. , “Adding Diane Dorman is just the ...
(Date:2/9/2016)... Feb. 9, 2016 BERG, a biopharmaceutical ... research approach, has announced the appointment of ... Chief Operating Officer. Haddock brings to BERG over ... 12 years in senior financial functions at pharmaceutical ... business organizational management. Niven R. ...
(Date:2/8/2016)... , February 8, 2016 ... Oncology Private Limited, an innovation-driven oncology company developing ... and less toxic, today announced that chairman emeritus ... has invested in the company as part of ... round, joining existing investors Navam Capital and Aarin ...
Breaking Biology Technology:
(Date:2/1/2016)... , Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ) announces ... personality, Joey Fatone . Las Vegas , ... --> Las Vegas , where Joey appeared ... The new video ad was filmed at the Consumer Electronics Show ... the Wocket booth to meet and greet fans. ...
(Date:1/25/2016)... Jan. 25, 2016   Unisys Corporation (NYSE: UIS ... F. Kennedy (JFK) International Airport, New York City ... identify imposters attempting to enter the United States ... them. pilot testing of the system at Dulles ... terminals at JFK during January 2016. --> pilot testing ...
(Date:1/22/2016)... 22, 2016 ... the "Global Biometrics Market in Retail ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ... Biometrics Market in Retail Sector 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ...
Breaking Biology News(10 mins):